Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAetna suprachoroidal Xipere Coverage & Prior Auth …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0777

    Novel Injection Methods

    Customize your policy alerts

    Sign up for Aetna Policy 0777 alerts

    Get alerted when Policy 0777 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for novel ophthalmic injection methods (suprachoroidal injections, subretinal rtPA, and vessel-wall micro-infusion devices) affecting providers who perform or bill for these procedures and related drugs.

    Policy Summary
    PayerAetna
    PolicyNovel Injection Methods
    Policy CodePolicy 0777
    Change TypeMinor / administrative
    Effective DateFeb 6, 2009
    Last ReviewFeb 9, 2024
    Next Review DateAug 22, 2024
    Key ActionObtain prior authorization and submit the listed CPT/HCPCS and ICD-10 codes when billing for suprachoroidal triamcinolone (Xipere) or subretinal rtPA.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1Medically necessary Xipere
    1Medically necessary rtPA
    1Device investigational
    67516, J3299Key codes discussed
    H35.81; H35.60-H35.63ICD-10 listed

    Coverage Criteria

    Suprachoroidal triamcinolone (Xipere) for macular edema associated with uveitis

    Covered when ALL of the following are met:

    Suprachoroidal Xipere coverage: Suprachoroidal injection of triamcinolone acetonide injectable suspension (Xipere) is medically necessary for treatment of macular edema associated with uveitis when criteria are met in CPB 1000 Triamcinolone Acetonide Injectable Suspension (Xipere).

    See referenced CPB 1000 for specific selection criteria.

    Subretinal injection of rtPA for sub-macular hemorrhage

    Covered when ALL of the following are met:

    Subretinal rtPA coverage: Subretinal injection of recombinant tissue plasminogen activator (rtPA) is medically necessary for treatment of sub-macular hemorrhage.

    Procedure CPT 0810T applies; recombinant rtPA has no specific HCPCS code listed in this policy. Cite appropriate ICD-10 diagnosis codes for retinal hemorrhage (e.g., H35.60–H35.63).

    Suprachoroidal delivery of other pharmacologic agents

    Not covered / investigational:

    Other suprachoroidal agents: Suprachoroidal injection of all other pharmacologic agents (other than triamcinolone acetonide/Xipere) is considered experimental and investigational for all indications because effectiveness has not been established.

    Claims for these uses are subject to denial.

    Mercator Bullfrog micro-infusion device

    Not covered / investigational:

    Mercator Bullfrog device: The Mercator Bullfrog micro-infusion device is considered experimental and investigational for direct adventitial delivery of diagnostic or therapeutic agents via blood vessel walls due to lack of evidence regarding safety and effectiveness.

    Includes related HCPCS code C9759; use may be denied.

    Evidence-summary and investigational stance for novel injection methods

    Summarized coverage-relevant conclusions and evidence limits from the document:

    Suprachoroidal CLS-TA for NIU and related posterior segment disease: Small preclinical and clinical studies (including AZALEA, PEACHTREE and other trials) demonstrated favorable posterior tissue distribution, prolonged therapeutic levels, and clinically meaningful safety and efficacy signals (notably low rates of IOP elevation and cataract events); however, trials are limited by small sample sizes, some open-label designs, and lack of larger controlled studies.

    Further larger controlled trials are needed to establish definitive safety and effectiveness.

    Suprachoroidal CLS-TA plus intravitreal aflibercept for DME: A randomized controlled study (Barakat et al) in treatment‑naive DME (n=36 active, n=35 control) showed no statistically significant difference in mean BCVA change at 24 weeks between combination therapy and aflibercept monotherapy, with modestly greater CST improvement in some analyses and fewer total treatments in the active group; authors recommend larger and longer studies to confirm findings.

    Study eligibility included BCVA 20–70 letters and CST >300 μm.

    Suprachoroidal hyaluronic acid hydrogel for IOP reduction: Preclinical rabbit studies demonstrated that in situ-forming hyaluronic acid hydrogel injected into the SCS reduced intraocular pressure for over 1 month, and optimized formulations achieved reductions up to 4 months; human trials are needed.

    This policy notes that Aetna covers suprachoroidal injection of triamcinolone acetonide injectable suspension (Xipere) for macular edema associated with uveitis when the criteria in CPB 1000 are met. For other pharmacologic agents delivered to the suprachoroidal space, coverage is not established and those uses are considered experimental and investigational. Relevant billing guidance identifies CPT 67516 and HCPCS J3299 for Xipere when selection criteria are satisfied; providers should follow the referenced CPB for specific patient selection and documentation requirements.

    Clinical and preclinical reports emphasize that not all agents are suitable for suprachoroidal space (SCS) injection because some molecules, particularly highly aqueous-soluble agents, are cleared rapidly from the SCS. Studies to date predominantly used CLS-TA (Xipere) because it demonstrates favorable posterior distribution and slower clearance; additional formulation work or delivery strategies are needed to enable sustained therapeutic levels for other agents. Providers should be aware that rapid SCS clearance and limited targeting to posterior segments are key biologic limitations that affect suitability of alternative drugs for this route.

    Aetna considers suprachoroidal injection of all pharmacologic agents other than triamcinolone acetonide (Xipere) to be not medically necessary / experimental and investigational for all indications because effectiveness has not been established. Claims for these uses are subject to denial.

    The Mercator Bullfrog micro-infusion device is described as a balloon‑tipped, micro‑needle system intended to deliver agents into adventitial or peri‑vascular tissues. Although it has FDA 510(k) clearance for selected peripheral and coronary vessel uses, Aetna considers use of this device for direct adventitial delivery in the contexts described by this policy to be experimental and investigational due to a lack of evidence demonstrating safety and effectiveness; such uses may be considered not medically necessary and are subject to denial. The related HCPCS code is C9759.

    Coding

    Covered CPT Codes (suprachoroidal - when selection criteria met)CPTCovered
    67516Suprachoroidal space injection of pharmacologic agent (separate procedure)
    Covered HCPCS Codes (Xipere)HCPCSCovered
    J3299Injection, triamcinolone acetonide (Xipere), 1 mg
    CPT codes not covered for other suprachoroidal indicationsCPTNot Covered
    0699TInjection, posterior chamber of eye, medication
    67516Suprachoroidal space injection of pharmacologic agent (separate procedure)
    ICD-10 codes (covered indications)ICD-10
    H35.81Retinal edema
    H35.60Retinal hemorrhage, unspecified
    H35.61Retinal hemorrhage, preretinal
    H35.62Retinal hemorrhage, subretinal
    H35.63Retinal hemorrhage, intraretinal
    No explicit billing codes in this sectionmixed
    No codes listed
    Central subfield thickness (CST) — > 300 µm (used to define macular edema in cited trial)
    Definition> 300 µm — threshold used to define macular edema in cited clinical trials (AZALEA, Henry et al.)
    Context of useUsed as an OCT-derived central subfield thickness (CST) threshold to identify study participants with macular edema
    Source trial exampleHenry et al. prospective multi-center study: based on CST > 300 µm, 20 of 38 subjects had macular edema at baseline
    Central subfield thickness (CST) eligibility used in study — > 300 μm
    Eligibility threshold> 300 μm (central subfield thickness) — entry criterion for the Barakat et al. DME study

    Provider Actions and Billing Guidance

    Prior Authorization

    Prior Authorization Required

    Prior authorization is expected for covered suprachoroidal injection of triamcinolone acetonide (Xipere) when medical necessity criteria are met. Submit the appropriate CPT/HCPCS along with an ICD-10 diagnosis that supports the indication.

    • Covered codes when criteria met: CPT 67516; HCPCS J3299 (Xipere, 1 mg); ICD-10 H35.81 (Retinal edema).
    • Do not submit CPT 67516 or 0699T, or HCPCS C9759, for suprachoroidal delivery of non‑Xipere agents — these are not covered in this CPB.
    Documentation Required

    Clinical Trial Eligibility Documentation

    Document clinical trial eligibility elements when applicable. For studies of suprachoroidal agents combined with intravitreal therapy, include prior treatment history, baseline best-corrected visual acuity (BCVA), central subfield thickness (CST), and pre-specified retreatment criteria (eg, timing and BCVA/CST thresholds).

    Background

    Background: The posterior segment of the eye — including the retina, macula and choroid — is relatively difficult to access. Traditional delivery approaches include intravitreal and peri‑ocular injections and implants. The suprachoroidal space (SCS) has been investigated as an alternative route to target posterior tissues, with the potential advantage of higher local posterior‑segment exposure and reduced anterior segment exposure, but practical challenges remain in reliably delivering and retaining drugs at the posterior pole.

    Definitions

    Suprachoroidal space (SCS) — definition and purpose
    DefinitionThe suprachoroidal space (SCS) is the potential anatomic space between the sclera and the choroid used as a route for targeted drug delivery to posterior segment tissues.
    Access techniqueCan be accessed via hollow micro-needles or microcannulae fitted to scleral thickness and visualized with OCT
    Therapeutic rationaleProvides a route from anterior to posterior eye enabling higher drug concentrations in chorio-retinal tissues with potentially reduced anterior segment exposure
    CLS-TA / Xipere — definition and intended use
    ProductTriamcinolone acetonide injectable suspension (CLS-TA; marketed as Xipere) — proprietary formulation for suprachoroidal administration
    Intended use
    Policy Summary
    PayerAetna
    PolicyNovel Injection Methods
    Policy CodePolicy 0777
    Change TypeMinor / administrative
    Effective DateFeb 6, 2009
    Last ReviewFeb 9, 2024
    Next Review DateAug 22, 2024
    Key ActionObtain prior authorization and submit the listed CPT/HCPCS and ICD-10 codes when billing for suprachoroidal triamcinolone (Xipere) or subretinal rtPA.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Billing GuidanceBackgroundDefinitions

    Currently preclinical evidence only.

    Mercator Bullfrog micro-infusion device: The Bullfrog device has FDA 510(k) clearance for infusion into vessel walls/perivascular areas for peripheral and coronary vessels; published literature reports technical feasibility and early safety work, but there is insufficient evidence regarding safety and effectiveness for the broader clinical uses described, supporting an investigational stance for these indications.

    May be denied for indications lacking supporting clinical evidence; includes HCPCS C9759.

    Subretinal rtPA for submacular hemorrhage: The American Academy of Ophthalmology lists subretinal injection of recombinant tPA as a therapeutic option for submacular hemorrhage.

    Procedure CPT 0810T applies; clinical judgment required for patient selection.

    Measurement modalityOCT-derived central subfield thickness (CST) used to assess retinal edema
    Study populationApplied to treatment‑naive DME subjects enrolled in the randomized, double-masked study
    Best-corrected visual acuity (BCVA) eligibility used in study — 20 to 70 letters
    BCVA eligibility range20 to 70 letters — inclusion criterion in the Barakat et al. DME trial
    PurposeDefines visual acuity bounds for enrollment in the randomized CLS-TA plus aflibercept versus aflibercept study
    AssessmentBest-corrected visual acuity (BCVA) measured in letter score (ETDRS) format
    • Trials commonly enrolled treatment‑naive patients with BCVA 20–70 letters and CST >300 μm.
    • Report retreatment schedule and any as‑needed (PRN) dosing criteria used in the trial (eg, weeks allowed for additional intravitreal therapy).
    Denial Risk

    Experimental Suprachoroidal Agents

    Suprachoroidal delivery of pharmacologic agents other than triamcinolone acetonide injectable suspension (Xipere) is considered experimental and investigational for all indications due to insufficient evidence of safety and effectiveness. Do not bill covered suprachoroidal codes for these agents.

    • Experimental suprachoroidal agents: any pharmacologic agent delivered suprachoroidally other than Xipere.
    • Do not use CPT/HCPCS listed as covered for Xipere when the agent is not Xipere; such use may be denied as experimental.
    Step Therapy

    Comparative Step Considerations

    Comparative step considerations: when suprachoroidal CLS‑TA has been studied in combination with intravitreal aflibercept, studies showed similar mean BCVA gains versus aflibercept monotherapy but greater CST reduction and fewer total treatments in the combination arm. Consider that combination therapy may reduce number of intravitreal treatments but has not shown superior BCVA in the referenced trial.

    • Active group (CLS‑TA + aflibercept) vs aflibercept monotherapy: similar BCVA change at 24 weeks; greater CST reduction in active group; fewer scheduled plus as‑needed treatments (average 2.6 vs 4.6).
    • No treatment‑related serious adverse events observed in the referenced study.
    Denial Risk

    Investigational Device Risk

    Investigational device risk: the Mercator Bullfrog micro‑infusion device is considered experimental and investigational for adventitial delivery via blood vessel walls due to lack of evidence on safety and effectiveness; claims for its use (eg, HCPCS C9759) may be denied.

    • Bullfrog device: experimental/investigational for direct adventitial delivery — lack of clinical evidence.
    • Billing note: HCPCS C9759 (transcatheter intraoperative blood vessel microinfusion) is listed as not covered for indications in this CPB and may be denied.
    Developed for treatment of macular edema associated with non-infectious uveitis and investigated for other posterior segment diseases
    Clinical contextStudied in phase I/II and other trials (e.g., AZALEA, PEACHTREE) showing favorable posterior tissue distribution and preliminary safety/efficacy signals
    Subretinal rtPA — definition
    DefinitionSubretinal rtPA — recombinant tissue plasminogen activator delivered via subretinal injection to treat sub-macular hemorrhage
    Procedure coding noteProcedure CPT 0810T applies for subretinal injection of a pharmacologic agent including vitrectomy and retinotomies
    Clinical guidanceAAO and referenced literature list subretinal rtPA as a therapeutic option for submacular hemorrhage
    Suprachoroidal space (SCS) — alternate mention/definition
    Alternate definitionThe SCS is the potential space between the sclera and choroid that can be used to deliver therapeutics to the back of the eye
    Visualization and accessSCS can be visualized with advanced OCT techniques and accessed safely via microneedles or microcannulae
    Pharmacokinetic noteSCS injections may achieve higher target-tissue concentrations but highly aqueous soluble molecules clear more rapidly from the SCS
    CLS-TA — formulation and investigational contexts
    FormulationCLS-TA is a triamcinolone acetonide injectable suspension formulated for suprachoroidal administration (examples: 4 mg in 100 μl used in early trials)
    Investigational contextsStudied in phase I/II open-label and multi-center trials for non-infectious uveitis and macular edema (e.g., Goldstein 2016, Henry et al. 2022, AZALEA/PEACHTREE)
    Safety signalsTrials reported predominantly mild-to-moderate adverse events, low steroid-related IOP increases in some studies, and preliminary efficacy in reducing macular edema